ArticleNpj biosensing2025
A passive blood separation sensing platform for point-of-care devices.
Article in Npj biosensing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Multiplexed nanophotonic sensor arrays for time-resolved biomolecular analysis.Biosensors & bioelectronics · 2026Article
- Centrifuge-free separation of plasma from milliliters of whole blood for point-of-care diagnostics.Lab on a chip · 2026Article
- Emerging Microfluidic Plasma Separation Technologies for Point-of-Care Diagnostics: Moving Beyond Conventional Centrifugation.Biosensors · 2025Review
- Cancer and Aging Biomarkers: Classification, Early Detection Technologies and Emerging Research Trends.Biosensors · 2025Review
- Ultrasensitive Alzheimer's disease biomarker detection with nanopillar photonic crystal biosensors.Optica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The blood test is one of the most performed investigations in clinical practice, with samples typically analysed in a centralised laboratory. Many of these tests monitor routine conditions that would benefit from a point-of-care approach, reducing the burden on practitioners, patients and healthcare systems. Such a decentralised model requires the development of sophisticated, yet easy-to-use technology; however, platforms that combine high-performance with low-cost and simplicity remain scarce. Moreover, most research papers only address a subset of requirements and study specific aspects in isolation. A systems approach that considers the interplay between each element of the technology is clearly required to develop a coherent solution. Here, we present such a systems approach in the context of testing for C-reactive protein (CRP), a commonly requested test in clinical practise that indicates inflammation and is particularly relevant for monitoring patients with chronic diseases, e.g. those with rheumatoid arthritis or who are undergoing cancer therapy. The approach we take here features an entirely passive microfluidic cartridge for blood separation, integrated with a high-performance sensing platform which we have tested in a real-world context. The device is compatible with a handheld detection unit and is simple to use yet can accurately detect CRP levels at clinically relevant levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.